Current stage-Stage IV (Advanced) Posts on Medivizor
Navigation Menu

Current stage-Stage IV (Advanced) Posts on Medivizor

Evaluating the long-term outcomes of Zevalin for patients with advanced B cell lymphoma

Posted by on Jan 10, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of patients with advanced (stage 3 – 4) non-Hodgkin’s lymphoma (NHL) who received radioimmunotherapy before allogeneic stem cell transplantation (alloSCT). This study concluded that this treatment regimen improved survival in most of these patients. Some background AlloSCT involves...

Read More

Evaluating intensive first-line treatment for patients with advanced Hodgkin’s lymphoma

Posted by on Nov 27, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of patients with advanced Hodgkin’s lymphoma (HL) who received intensive first-line treatment. This study concluded that intensive first-line treatment with or without radiotherapy led to better long-term outcomes in these patients. Some background For patients with advanced HL,...

Read More

Long-term outcomes of radioimmunotherapy in patients with follicular lymphoma

Posted by on Oct 5, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the long-term outcomes of radioimmunotherapy following first-line (primary) R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated patients with advanced-stage follicular lymphoma (FL). This study concluded that this treatment approach is effective and well-tolerated in...

Read More

Comparing obinutuzumab and rituximab in first-line chemotherapy regimens for follicular lymphoma

Posted by on Jul 2, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of obinutuzumab (Gazyva) versus rituximab (Rituxan) plus chemotherapy for previously untreated follicular lymphoma. This study concluded that obinutuzumab improved survival outcomes compared to rituximab. Some background Follicular lymphoma is the most common type of...

Read More

What are the outcomes for advanced HL patients receiving intensified BEACOPP chemotherapy after ABVD chemotherapy?

Posted by on Feb 9, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the outcomes of advanced-stage classical Hodgkin’s lymphoma (HL) patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy followed by escalated (higher dose) BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) chemotherapy...

Read More

Does biosimilar filgrastim improve neutropenia in older DLBCL patients receiving chemotherapy?

Posted by on Dec 20, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study analyzed the outcomes of older patients with stage 3 or 4 DLBCL (diffuse large B-cell lymphoma) who received biosimilar filgrastim (Neupogen) during their chemotherapy. The study concluded that filgrastim was safe and effective in these patients. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common type...

Read More

Is changing treatment intensity after PET scan effective for patients with advanced stage Hodgkin lymphoma?

Posted by on Dec 6, 2017 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at changing treatment intensity after a PET scan for patients with advanced stage Hodgkin lymphoma. The authors concluded that reducing treatment intensity for patients with a negative PET scan can reduce negative side effects and improve long-term outcomes. Some background Advanced stage Hodgkin lymphoma (HL) can...

Read More

Comparison between rituximab and CT-P10 biosimilar medication for the treatment of patients with advanced stage follicular lymphoma

Posted by on Oct 7, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared rituximab (Rituxan) and CT-P10 treatments for patients with previously untreated advanced stage follicular lymphoma. The study concluded that CT-P10 is just as safe and effective as name-brand rituximab.  Some background Follicular lymphoma (FL) is a type of non-Hodgkin lymphoma. It is commonly treated...

Read More

Combining bendamustine and rituximab improves time to disease progression in follicular and mantle-cell lymphomas

Posted by on Jun 14, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the use of the combination of bendamustine (Treanda) and rituximab (Rituxan) as a firstline treatment in patients with follicular or mantle cell lymphoma. This study concluded that this treatment combination was more effective than the standard treatment of rituximab plus CHOP chemotherapy. Some background The...

Read More

What is the most effective chemotherapy combination for advanced follicular lymphoma?

Posted by on May 30, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared different chemotherapy regimens and rituximab (Rituxan) for the initial treatment of advanced follicular lymphoma. This study concluded that the combinations R-CHOP and R-FM were more effective than R-CVP. R-CHOP was associated with fewer severe side effects than R-FM. Some background Follicular lymphoma (FL) is...

Read More

Adding rituximab to escalated BEACOPP therapy in Hodgkin Lymphoma patients with a positive PET scan

Posted by on May 15, 2017 in Hodgkin's lymphoma | 0 comments

In a nutshell This study assessed the effectiveness of using escalated BEACOPP plus rituximab chemotherapy in patients with advanced stage Hodgkin Lymphoma. The study concluded that adding rituximab to the standard escalated BEACOPP regimen did not significantly improve time to disease progression. Some background Hodgkin Lymphoma (HL) is...

Read More

Treatment options for advanced Hodgkin lymphoma

Posted by on Dec 20, 2016 in Hodgkin's lymphoma | 0 comments

In a nutshell This review discussed the current and future treatment options for advanced Hodgkin lymphoma (stage III or IV). Some background While early-stage Hodgkin lymphoma has very high remission rates, rates for advanced disease are generally lower. The standard treatment option for advanced Hodgkin lymphoma is ABVD chemotherapy...

Read More